Persistence of Transgene Expression in Synovium

滑膜中转基因表达的持久性

基本信息

  • 批准号:
    6800409
  • 负责人:
  • 金额:
    $ 29.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-15 至 2007-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Progress toward the clinical application of gene therapy for arthritis has been slowed by the inability to sustain intraarticular transgene expression. The prevailing observation is that transgene expression persists for only two to three weeks. The current proposal is designed to test the following hypotheses: 1) The immunologic incompatibility of foreign (non-self) transgene products leads to this premature termination of transgene expression, 2) Specific cell types within the synovium are capable of supporting stable, persistent transgene expression, and 3) In normal, immunocompetent animals, expression of cDNAs encoding homologous (self) or immunologically compatible gene products will persist long-term within the synovium. To determine the relative benefits and limitations of various ex vivo and in vivo gene delivery systems, each will be evaluated for transgenic persistence in the knees of athymic, nude rats. Because transduced cells that express foreign proteins survive for their natural life-span in this animal, it will serve as a "pseudohomologous" system within which we can use diagnostic marker genes to simulate the delivery of transgenes encoding "self" proteins to normal joints. Using the cDNA for Green Fluorescent Protein to phenotypically tag genetically modified cells in the synovium, we will use flow cytometry to characterize the populations of transduced cells. By studying how they change with time, we will identify the specific cell populations within the synovial lining that may permit long-term expression. The true motivation behind the study is however to determine for how long exogenous transgenes may be expressed in normal and arthritic joints in immunocompetent animals. For this, two different gene systems will be studied in normal rats that will not activate immune clearance. The first will be a soluble form of the rat TNF receptor type II; the second will be a "gene" construct that is transcribed, but not translated, avoiding altogether the immune issues of foreign protein products. The following specific aims will be addressed: 1) To comparatively evaluate synovial fibroblasts, dermal fibroblasts and mesenchymal stem cells for their capacity to enable persistent transgenic expression, and their biodistribution when used as vehicles for ex vivo intra-articular gene delivery to the knees of athymic nude rats, 2) To comparatively evaluate recombinant lentivirus, AAV and high capacity adenovirus for their capacity to enable persistent transgenic expression and their biodistribution when used as vehicles for direct intraarticular gene delivery to the knees of athymic nude rats, 3) To characterize genetically modified cell populations in the synovium and to determine how they change with time in vivo, and 4) Within immunocompetent rats, evaluate persistence of expression using immunocompatible transgene systems in normal and arthritic knees following ex vivo and in vivo delivery.
描述(由申请人提供): 关节炎基因治疗的临床应用进展由于不能维持关节内转基因表达而减缓。普遍的观察是转基因表达仅持续两到三周。本提案旨在检验以下假设:1)外源性免疫不相容性(非自身)转基因产物导致转基因表达的这种过早终止,2)滑膜内的特定细胞类型能够支持稳定、持续的转基因表达,和3)在正常的免疫活性动物中,编码同源(自身)或免疫相容基因产物的cDNA的表达将在滑膜内长期存在。为了确定各种离体和体内基因递送系统的相对益处和局限性,将评价每种系统在无胸腺裸大鼠膝关节中的转基因持久性。因为表达外源蛋白的转导细胞在这种动物中存活了它们的自然寿命,它将作为一个“假同源”系统,在该系统中,我们可以使用诊断标记基因来模拟编码“自身”蛋白的转基因向正常关节的递送。使用绿色荧光蛋白的cDNA表型标记滑膜中的遗传修饰细胞,我们将使用流式细胞术表征转导细胞的群体。通过研究它们如何随时间变化,我们将确定滑膜衬里内可能允许长期表达的特定细胞群。然而,这项研究背后的真正动机是确定外源性转基因在免疫活性动物的正常关节和关节炎关节中表达的时间。为此,将在不会激活免疫清除的正常大鼠中研究两种不同的基因系统。第一种是大鼠TNF受体II型的可溶形式;第二种是转录但不翻译的“基因”构建体,完全避免了外源蛋白产物的免疫问题。将处理以下具体目标:1)为了比较地评估滑膜成纤维细胞、真皮成纤维细胞和间充质干细胞能够持续转基因表达的能力,以及它们在用作离体关节内基因递送至无胸腺裸大鼠膝盖的载体时的生物分布,AAV和高容量腺病毒在用作将基因直接关节内递送至无胸腺裸大鼠膝关节的载体时能够实现持续的转基因表达和它们的生物分布,3)表征滑膜中遗传修饰的细胞群并确定它们如何在体内随时间变化,以及4)在免疫活性大鼠中,评价在离体和体内递送后使用免疫相容性转基因系统在正常和关节炎膝关节中的表达的持久性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven C Ghivizzani其他文献

Will arthritis gene therapy become a clinical reality?
关节炎基因疗法会成为临床现实吗?
  • DOI:
    10.1038/ncprheum0215
  • 发表时间:
    2006-07-01
  • 期刊:
  • 影响因子:
    32.700
  • 作者:
    Christopher H Evans;Steven C Ghivizzani;Paul D Robbins
  • 通讯作者:
    Paul D Robbins

Steven C Ghivizzani的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven C Ghivizzani', 18)}}的其他基金

Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
  • 批准号:
    8675729
  • 财政年份:
    2010
  • 资助金额:
    $ 29.27万
  • 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
  • 批准号:
    8129527
  • 财政年份:
    2010
  • 资助金额:
    $ 29.27万
  • 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
  • 批准号:
    8277448
  • 财政年份:
    2010
  • 资助金额:
    $ 29.27万
  • 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
  • 批准号:
    8476987
  • 财政年份:
    2010
  • 资助金额:
    $ 29.27万
  • 项目类别:
Delivery of Soluble FGFR3 as a Treatment for Achondroplasia
递送可溶性 FGFR3 作为软骨发育不全的治疗方法
  • 批准号:
    7987228
  • 财政年份:
    2010
  • 资助金额:
    $ 29.27万
  • 项目类别:
5th international meeting of gene and cell therapies for arthritis and related di
第五届关节炎及相关疾病基因和细胞疗法国际会议
  • 批准号:
    7407749
  • 财政年份:
    2007
  • 资助金额:
    $ 29.27万
  • 项目类别:
5th international meeting of gene and cell therapies for arthritis and related di
第五届关节炎及相关疾病基因和细胞疗法国际会议
  • 批准号:
    7616969
  • 财政年份:
    2007
  • 资助金额:
    $ 29.27万
  • 项目类别:
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease
AAV 血清型在基因递送治疗慢性关节疾病中的应用
  • 批准号:
    8056625
  • 财政年份:
    2003
  • 资助金额:
    $ 29.27万
  • 项目类别:
Utility of AAV serotypes for gene delivery in treatment of chronic joint disease
AAV 血清型在基因递送治疗慢性关节疾病中的应用
  • 批准号:
    8230717
  • 财政年份:
    2003
  • 资助金额:
    $ 29.27万
  • 项目类别:
Gene Delivery to Cartilage Defects via Marrow Coagulates
通过骨髓凝固将基因传递至软骨缺陷
  • 批准号:
    7250841
  • 财政年份:
    2003
  • 资助金额:
    $ 29.27万
  • 项目类别:

相似国自然基金

Lentivirus载体转染骨髓间质干细胞诱导增殖和成骨细胞定向分化修复骨缺损的研究
  • 批准号:
    30371434
  • 批准年份:
    2003
  • 资助金额:
    20.0 万元
  • 项目类别:
    面上项目

相似海外基金

Lentivirus Construct Core
慢病毒构建核心
  • 批准号:
    10630391
  • 财政年份:
    2023
  • 资助金额:
    $ 29.27万
  • 项目类别:
Improving the production and quality of lentivirus for the transduction of haematopoeitic stem cells via a perfusion culture process
通过灌注培养过程提高用于转导造血干细胞的慢病毒的产量和质量
  • 批准号:
    2734111
  • 财政年份:
    2022
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Studentship
Lentivirus Rev protein: characterization and study of Rev - nucleolar protein interactions
慢病毒 Rev 蛋白:Rev - 核仁蛋白相互作用的表征和研究
  • 批准号:
    RGPIN-2016-06532
  • 财政年份:
    2022
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Discovery Grants Program - Individual
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure
慢病毒样颗粒将 Cas12 核糖核蛋白 (RNP) 特异性递送至体内 HIV 储存细胞以治疗 HIV
  • 批准号:
    10598912
  • 财政年份:
    2022
  • 资助金额:
    $ 29.27万
  • 项目类别:
Improving the production and quality of lentivirus for the transduction of haematopoeitic stem cells via a perfusion culture process
通过灌注培养过程提高用于转导造血干细胞的慢病毒的产量和质量
  • 批准号:
    2585771
  • 财政年份:
    2021
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Studentship
Lentivirus Rev protein: characterization and study of Rev - nucleolar protein interactions
慢病毒 Rev 蛋白:Rev - 核仁蛋白相互作用的表征和研究
  • 批准号:
    RGPIN-2016-06532
  • 财政年份:
    2020
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Discovery Grants Program - Individual
Repertoire-scale T cell antigen identification via peptide-MHC lentivirus display
通过肽-MHC 慢病毒展示进行全库规模 T 细胞抗原鉴定
  • 批准号:
    10001123
  • 财政年份:
    2020
  • 资助金额:
    $ 29.27万
  • 项目类别:
Lentivirus persistence in the brain: viral, host and therapeutic determinants
慢病毒在大脑中的持久性:病毒、宿主和治疗决定因素
  • 批准号:
    401955
  • 财政年份:
    2019
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Operating Grants
Development of a scalable and consistent process for the production of lentivirus for gene-modified cell therapies
开发用于基因修饰细胞疗法的慢病毒生产的可扩展且一致的工艺
  • 批准号:
    2246819
  • 财政年份:
    2019
  • 资助金额:
    $ 29.27万
  • 项目类别:
    Studentship
Lentivirus Replication Strategy and Pathogenesis
慢病毒复制策略和发病机制
  • 批准号:
    10700321
  • 财政年份:
    2018
  • 资助金额:
    $ 29.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了